

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MERCK SHARP & DOHME LLC,
Petitioner

v.

POGONA, LLC,
Patent Owner.

Case No. IPR2026-00221
U.S. Patent No. 11,058,757

PETITIONER'S UPDATED LIST OF EXHIBITS

LIST OF EXHIBITS

Ex. No.	Description
Ex-1001	U.S. Patent No. 11,058,757 (“the ’757 Patent”)
Ex-1002	Declaration of Dr. Dennis Kasper
Ex-1003	Curriculum Vitae of Dr. Dennis Kasper
Ex-1004	Prosecution History of U.S. Patent No. 11,058,757
Ex-1005	International Publication No. WO 2014/118201 (“Porro”)
Ex-1006	International Publication No. WO 2017/011338 (“Mekalanos”)
Ex-1007	U.S. Patent No. 8,808,707 (“Siber”)
Ex-1008	International Publication No. WO 2016/149771 (“Babb”)
Ex-1009	International Publication No. WO 2016/207905 (“Matur”)
Ex-1010	International Publication No. WO 2015/121783 (“Gu”)
Ex-1011	Keith P. Klugman et al., <i>Pneumococcal Conjugate Vaccine and Pneumococcal Common Protein Vaccines</i> , in <i>Vaccines</i> 504 (Stanley A. Plotkin, Walter A. Orenstein & Paul A. Offit eds., 6th ed. 2013); Lisa A. Jackson, <i>Pneumococcal Polysaccharide Vaccines</i> , in <i>Vaccines</i> 542 (Stanley A. Plotkin, Walter A. Orenstein & Paul A. Offit eds., 6th ed. 2013) (“Plotkin”)
Ex-1012	K. Aaron Geno et al., <i>Pneumococcal Capsules and Their Types: Past, Present, and Future</i> , 28 <i>Clin. Microbiol. Rev.</i> 871, 871–899 (2015) (“Nahm”)
Ex-1013	Mekalanos Provisional - Provisional Application No. 62/191,028
Ex-1014	Mekalanos Redline with Provisional
Ex-1015	Prosecution History of U.S. Application No. 17/347,435 (CON to ’757 Patent)

Ex. No.	Description
Ex-1016	<i>Physicians' Desk Reference</i> 3403–9 (65th ed. 2011) (“PDR 2011 Prevnar 13®”)
Ex-1017	G.H.J. Wagenvoort et al., <i>Risk and Outcomes of Invasive Pneumococcal Disease in Adults with Underlying Conditions in the Post-PCV7 Era, The Netherlands</i> , 34 <i>Vaccine</i> 334–40 (2016) (“Wagenvoort”)
Ex-1018	Mark T. Dransfield et al., <i>Superior Immune Response to Protein-Conjugate Versus Free Pneumococcal Polysaccharide Vaccine in Chronic Obstructive Pulmonary Disease</i> , 180 <i>Am. J. Respir. Crit. Care Med.</i> 499–505 (2009) (“Dransfield”)
Ex-1019	Marta Domenech et al., <i>Emerging, Non-PCV13 Serotypes 11A and 35B of Streptococcus pneumoniae Show High Potential for Biofilm Formation In Vitro</i> , 10 <i>PLoS One</i> e0125636 (2015) (“Domenech”)
Ex-1020	Sandra S. Richter et al., <i>Changes in Pneumococcal Serotypes and Antimicrobial Resistance After Introduction of the 13-Valent Conjugate Vaccine in the United States</i> , 58 <i>Antimicrob., Agents Chemother.</i> 6484, 6484–6493 (2014) (“Richter 2014”)
Ex-1021	International Publication No. WO 2007/034280 (“Blay”)
Ex-1022	International Publication No. WO 2006/065137 (“Nierop”)
Ex-1023	Matthias Imöhl et al., <i>Pneumococcal Meningitis and Vaccine Effects in the Era of Conjugate Vaccination: Results of 20 Years of Nationwide Surveillance in Germany</i> , 15 <i>BMC Infect. Dis.</i> 61 (2015) (“Imöhl”)
Ex-1024	Stefan Flasche et al., <i>Effect of Pneumococcal Conjugate Vaccination on Serotype-Specific Carriage and Invasive Disease in England: A Cross-Sectional Study</i> , 8 <i>PLoS Med.</i> e1001017 (2011) (“Flasche”)
Ex-1025	Sarkis K. Mazmanian & Dennis L. Kasper, <i>The Love–Hate Relationship Between Bacterial Polysaccharides and the Host Immune System</i> , 6 <i>Nat. Rev. Immunol.</i> 849 (2006) (“Mazmanian and Kasper 2006”)
Ex-1026	Stephen D. Bentley et al., <i>Genetic Analysis of the Capsular Biosynthetic Locus from All 90 Pneumococcal Serotypes</i> , 2 <i>PLoS Genet.</i> e31 (2006) (“Bentley”)

Ex. No.	Description
Ex-1027	<i>Explaining How Vaccines Work</i> , CDC, https://www.cdc.gov/vaccines/basics/explaining-how-vaccines-work.html (last visited Jan. 9, 2026) (“CDC”)
Ex-1028	S.K. Obaro, <i>The New Pneumococcal Vaccine</i> , 8 <i>Clin. Microbiol. Infect.</i> 623–33 (2002) (“Obaro”)
Ex-1029	P.H. Mäkelä, <i>Capsular Polysaccharide Vaccines Today</i> , 12 <i>Infection</i> S72 (1984) (“Mäkelä”)
Ex-1030	Rino Rappuoli et al., <i>On the Mechanisms of Conjugate Vaccines</i> , 116 <i>Proc. Nat’l Acad. Sci. U.S.</i> 14, 14–16 (2019) (“Rappuoli”)
Ex-1031	Oswald T. Avery & Walther F. Goebel, <i>Chemo-Immunological Studies on Conjugated Carbohydrate-Proteins: II. Immunological Specificity of Synthetic Sugar-Protein Antigens</i> , 50 <i>J. Exp. Med.</i> 533 (1929) (“Avery”)
Ex-1032	Porter Anderson et al., <i>Priming and Induction of Haemophilus influenzae Type b Capsular Antibodies in Early Infancy by Dpo20, an Oligosaccharide-Protein Conjugate Vaccine</i> , 111 <i>J. Pediatr.</i> 644, 644–650 (1987) (“Anderson 1987”)
Ex-1033	Peter J. Kniskern et al., <i>Haemophilus influenzae Type b Conjugate Vaccines</i> , in <i>Vaccine Design: The Subunit and Adjuvant Approach</i> 673 (Michael F. Powell & Mark J. Newman eds., 1995) (“Kniskern”)
Ex-1034	U.S. Patent No. 9,492,559 (“Emini”)
Ex-1035	International Publication No. WO 2011/100151 A1 (“Caulfield”)
Ex-1036	U.S. Patent No. 5,360,897 (“Anderson 1994”)
Ex-1037	INTENTIONALLY LEFT BLANK
Ex-1038	Nicole M. Payton et al., <i>Lyophilized Vaccine Development, in Practical Aspects of Vaccine Development</i> 297 (Parag Kolhe & Satoshi Ohtake eds., Academic Press 2022) (“Payton”)

Ex. No.	Description
Ex-1039	Gregory B. Lesinski & M.A.J. Westerink, <i>Novel Vaccine Strategies to T-Independent Antigens</i> , 47 <i>J. Microbiol. Methods</i> 135 (2001) (“Lesinski”)
Ex-1040	Mekalanos Claim Comparison with Provisional
Ex-1041	Adam Finn, <i>Bacterial Polysaccharide–Protein Conjugate Vaccines</i> , 70 <i>Br. Med. Bull.</i> 1 (2004) (“Finn”)
Ex-1042	Dennis L. Kasper et al., <i>Immune Response to Type III Group B Streptococcal Polysaccharide–Tetanus Toxoid Conjugate Vaccine</i> , 98 <i>J. Clin. Invest.</i> 2308 (1996) (“Kasper 1996”)
Ex-1043	Henry Shinefield et al., <i>Use of a Staphylococcus aureus Conjugate Vaccine in Patients Receiving Hemodialysis</i> , 346 <i>N. Engl. J. Med.</i> 491 (2002) (“Shinefield”)
Ex-1044	Feng-Ying C. Lin et al., <i>The Efficacy of a Salmonella typhi Vi Conjugate Vaccine in Two-to-Five-Year-Old Children</i> , 344 <i>N. Engl. J. Med.</i> 1263 (2001) (“Lin”)
Ex-1045	Victor Morais et al., <i>Conjugation Mechanism for Pneumococcal Glycoconjugate Vaccines: Classic and Emerging Methods</i> , 9 <i>Bioengineering</i> 774 (2022) (“Morais”)
Ex-1046	INTENTIONALLY LEFT BLANK
Ex-1047	Lawrence C. Paoletti et al., <i>Neonatal Mouse Protection against Infection with Multiple Group B Streptococcal (GBS) Serotypes by Maternal Immunization with a Tetravalent GBS Polysaccharide–Tetanus Toxoid Conjugate Vaccine</i> , 62 <i>Infect. Immun.</i> 3236 (1994) (“Paoletti”)
Ex-1048	Scott E. Johnson et al., <i>Correlation of Opsonophagocytosis and Passive Protection Assays Using Human Anticapsular Antibodies in an Infant Mouse Model of Bacteremia for Streptococcus pneumoniae</i> , 180 <i>J. Infect. Dis.</i> 133, 133–40 (1999) (“Johnson”)
Ex-1049	Robert L. Burton et al., <i>Development and Validation of a Fourfold Multiplexed Opsonization Assay (MOPA4) for Pneumococcal Antibodies</i> , 13 <i>Clin. Vaccine Immunol.</i> 1004 (2006) (“Burton”)

Ex. No.	Description
Ex-1050	Robert Malley et al., <i>Serotype-Independent Pneumococcal Experimental Vaccines That Induce Cellular as Well as Humoral Immunity</i> , 109 <i>Proc. Nat'l Acad. Sci. U.S.</i> 3623 (2012) (“Malley”)
Ex-1051	INTENTIONALLY LEFT BLANK
Ex-1052	International Publication No. WO 2017/067962 (“Bertaud”)
Ex-1053	<i>Physicians’ Desk Reference</i> 1182–83 (33d ed. 1979) (“PDR 1979 Pneumovax®”)
Ex-1054	<i>Physicians’ Desk Reference</i> 880–81, 1431–32 (44th ed. 1990) (“PDR 1990 Pneumovax® 23”)
Ex-1055	Nicholas J. Mantis et al., <i>Role of B Cells and Antibodies in Controlling Bacterial Pathogens</i> , in <i>Encyclopedia of Microbiology</i> 194–200 (Thomas M. Schmidt ed., 4th ed., Elsevier 2019) (“Mantis”)
Ex-1056	S.T. Sigurdardottir et al., <i>Safety and Immunogenicity of CRM197-Conjugated Pneumococcal–Meningococcal C Combination Vaccine (9vPnC-MnCC) Whether Given in Two or Three Primary Doses</i> , 26 <i>Vaccine</i> 4178, 4178–4186 (2008) (“Sigurdardottir”)
Ex-1057	Catherine Satzke et al., <i>Molecular Epidemiology of Streptococcus pneumoniae Serogroup 6 Isolates from Fijian Children, Including Newly Identified Serotypes 6C and 6D</i> , 48 <i>J. Clin. Microbiol.</i> 4298, 4298–4300 (2010) (“Satzke”)
Ex-1058	Sandra S. Richter et al., <i>Changing Epidemiology of Antimicrobial-Resistant Streptococcus pneumoniae in the United States, 2004–2005</i> , 48 <i>Clin. Infect. Dis.</i> e23 (2009) (“Richter 2009”)
Ex-1059	Yao KH et al., <i>Type distribution of serogroup 6 Streptococcus pneumoniae and molecular epidemiology of newly identified serotypes 6C and 6D in China</i> , 70 <i>Diag. Microbiol. Infect. Dis.</i> 291, 291–98 (2011) (“Yao”)

Ex. No.	Description
Ex-1060	James J. Calix et al., <i>Elucidation of structural and antigenic properties of pneumococcal serotype 11A, 11B, 11C, and 11F polysaccharide capsules</i> , 193 <i>J. Bacteriol.</i> 5271, 5271–5278 (2011) (“Calix”)
Ex-1061	<i>Emergence of PCV13 Nonvaccine-Specific Streptococcus Pneumoniae Serotypes 6C and 23A, and Serogroups 15, 33, and 35 Isolated from Children in Kansas City, Missouri</i> (2011) (“IDSA Abstract”)
Ex-1062	Sotera Stipulation Letter Regarding IPR Invalidity Grounds, <i>Pogona, LLC v. Merck Sharp & Dohme LLC</i> , No. 25-cv-15294 (D.N.J.) / IPR2026-00221

CERTIFICATE OF SERVICE

I hereby certify that on March 23, 2026, I caused a true and correct copy of the foregoing PETITIONER'S UPDATED LIST OF EXHIBIT was served in its entirety by filing these documents through the PTAB P-TACTS System, as well as by email, on the counsel of record for the Patent Owner:

Sarah E. Spires
Steven W. Hartsell
Ryan A. Hargrave
SKIERMONT DERBY LLP P.C.
1601 Elm Street, Suite 4400
Dallas, Texas 75201
Tel: (214) 978-6600
Fax: (214) 978-6601
Email: Pogona_SDTeam@skiermontderby.com

Dated: March 23, 2026

Respectfully submitted,

/s/ Ben Haber

Ben Haber (Reg. No. 67,129)
O'Melveny & Myers LLP
400 South Hope Street, 18th Floor
Los Angeles, CA 90071
Telephone: (213) 430-6000
Fax: (213) 430-6407
E-Mail: bhaber@omm.com
Attorney for Petitioner